Salud financiera de hoja de balance de Torrent Pharmaceuticals
Salud financiera controles de criterios 6/6
Torrent Pharmaceuticals tiene un patrimonio de accionistas total de ₹75.0B y una deuda total de ₹30.5B, lo que sitúa su ratio deuda-patrimonio en 40.6%. Sus activos y pasivos totales son ₹150.9B y ₹75.8B respectivamente. El BAIT de Torrent Pharmaceuticals es de ₹28.0B, por lo que su ratio de cobertura de intereses es de 9.8. Tiene efectivo e inversiones a corto plazo que ascienden a ₹12.4B.
Información clave
40.6%
Ratio deuda-patrimonio
₹30.48b
Deuda
| Ratio de cobertura de intereses | 9.8x |
| Efectivo | ₹12.35b |
| Patrimonio | ₹75.04b |
| Total pasivo | ₹75.84b |
| Activos totales | ₹150.88b |
Actualizaciones recientes sobre salud financiera
Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 03
Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly
Nov 14Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jun 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Mar 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 25Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly
Jan 04Recent updates
Earnings Miss: Torrent Pharmaceuticals Limited Missed EPS By 7.7% And Analysts Are Revising Their Forecasts
Oct 29Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Popularity With Investors Is Under Threat From Overpricing
Oct 24Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Just Reported And Analysts Have Been Lifting Their Price Targets
Jul 26Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark
Apr 16Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 03Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹22.00
Feb 05Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings
Jan 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly
Nov 14Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jun 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Mar 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 25Torrent Pharmaceuticals' (NSE:TORNTPHARM) Soft Earnings Don't Show The Whole Picture
Jun 02Estimating The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
May 25A Look At The Intrinsic Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Feb 18Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹25.00
Jan 27Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly
Jan 04Here's Why I Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is An Interesting Stock
Dec 14A Look At The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Nov 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Sep 30Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Deserve A Spot On Your Watchlist?
Sep 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 02I Ran A Stock Scan For Earnings Growth And Torrent Pharmaceuticals (NSE:TORNTPHARM) Passed With Ease
Jun 01Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Shares Could Be 30% Above Their Intrinsic Value Estimate
May 14Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 23Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (₹58.8B) de TORNTPHARM superan a sus pasivos a corto plazo (₹48.5B).
Pasivo a largo plazo: Los activos a corto plazo de TORNTPHARM (₹58.8B) superan a sus pasivos a largo plazo (₹27.4B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: El ratio deuda neta-patrimonio (24.2%) de TORNTPHARM se considera satisfactorio.
Reducción de la deuda: El ratio deuda-patrimonio de TORNTPHARM ha pasado de 118.6% a 40.6% en los últimos 5 años.
Cobertura de la deuda: La deuda de TORNTPHARM está bien cubierta por el flujo de caja operativo (111.8%).
Cobertura de intereses: Los pagos de intereses de la deuda de TORNTPHARM están bien cubiertos por el BAIT (9.8x cobertura).